SynBiotic SE (SBX.DE)
- Previous Close
3.0600 - Open
3.0850 - Bid --
- Ask --
- Day's Range
3.0750 - 3.3250 - 52 Week Range
2.5500 - 9.9000 - Volume
3,185 - Avg. Volume
3,440 - Market Cap (intraday)
18.04M - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2400 - Earnings Date Apr 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was incorporated in 2024 and is based in Munich, Germany.
www.synbiotic.com55
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SBX.DE
View MorePerformance Overview: SBX.DE
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SBX.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SBX.DE
View MoreValuation Measures
Market Cap
17.39M
Enterprise Value
18.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.76
Price/Book (mrq)
1.09
Enterprise Value/Revenue
4.73
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-275.31%
Return on Assets (ttm)
-13.92%
Return on Equity (ttm)
-61.58%
Revenue (ttm)
3.86M
Net Income Avi to Common (ttm)
-10.63M
Diluted EPS (ttm)
-2.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-78.21k